Biotech IV Monitor

KLRA — Kailera Therapeutics Inc.

$2.3B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Kailera Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.

Next readoutMay 2027in ~6 months
Upcoming readouts53 Phase 3
Market cap$2.3B
Cash & investments$1.17B~12 quarters at last loss rate
Recent 8-K filings1latest 2026-11-04

Upcoming readouts

Phase 2 Ribupatide
Obesity · NCT07458269
May 2027
Ongoing
Phase 2 KAI-7535
Obesity; Overweight · NCT07497880
July 2027
Ongoing
Phase 3 Ribupatide
Obesity; Overweight · NCT07284875
February 2028
Ongoing
Phase 3 Ribupatide
Obesity · NCT07284979
March 2028
Ongoing
Phase 3 Ribupatide
Obesity With Diabetes; Overweight With Diabetes · NCT07284901
March 2028
Ongoing

Cash position

Kailera Therapeutics Inc. reported $1.17B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $96M; at that rate the cash would last about 12 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion (1)

investor_1dcd1d42d ago
sounds cool
Track KLRA in real time
See live implied volatility for KLRA and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on KLRA
Contact — questions or corrections about KLRA: dukeupt@gmail.com